Today we hosted our virtual R&D Day where we shared updates and future development plans for #pemvidutide, our GLP-1/glucagon dual receptor agonist for #MASH as well as AUD and ALD.
Watch the full replay here: investorday.altimmune.com
00:00
Altimmune, Inc.
258 posts
Altimmune, Inc.
@AltimmuneInc
Late clinical-stage biotech developing differentiated therapies to improve the lives of those living with serious liver diseases.
- We presented data from our 48-week, placebo-controlled, Ph2 MOMENTUM trial of #pemvidutide for the treatment of #obesity at the #ADASciSessions, showcasing class leading preservation of lean mass, with 78.1% of weight loss coming from body fat: ir.altimmune.com/news-releases/…. #ADA2024
00:00 - In 2023 we released 48-week data from MOMENTUM, our Phase 2 #clinicaltrial of #pemvidutide for #obesity, received #FastTrack designation from #FDA for pemvidutide in #NASH/MASH and more. Explore our latest highlights and see what's next for Altimmune in 2024. #GLP1 #Glucagon
00:00 - #DYK there are more than 16 million people in the U.S. living with #NASH/MASH? Our CEO, Vipin Garg, shares his thoughts on the unmet need faced by #MASH patients, and the differentiating properties of #pemvidutide.
00:00 - Our CEO, Dr. Vipin Garg, connected with @BiotechTVHQ's @BradLoncar at #JPM24 to explore how investigational #pemvidutide's #GLP1/#Glucagon dual agonism works to treat obesity with the added benefit of reducing liver fat & addressing dyslipidemia: biotechtv.com/post/altimmune….SF Healthcare Week: @AltimmuneInc CEO Vipin Garg explains the science of weight loss drugs and makes the case for GLP-1/glucagon. $ALT Full video: biotechtv.com/post/altimmune…
00:00 - Our executive team is attending #JPM24 in San Francisco this week. Connect with us for 1x1 meetings to learn about our pipeline of next-generation medicines for #obesity, #NASH and #HepatitisB. #JPM2024
- At the @NashTagConf both Vlad Ratziu, M.D., and @AlkhouriNaim, M.D., presented data that highlighted potent reductions in #liverfat and cT1 w/#pemvidutide in subjects with #MASLD/#NAFLD. Learn more: nash-tag.org #NASHTAG2024
- Today, we announced the completion of our End-of-Phase 2 meeting with the U.S. FDA and agreement on the design of a Phase 3 registrational program for #pemvidutide in the treatment of #obesity. Learn more in the full release: ir.altimmune.com/news-releases/…
00:00 
00:00- Our CMO, Dr. Scott Harris, will be presenting on the role of glucagon-containing dual and triple agonists in the treatment of #obesity and #MASH at the Global MASLD Conference hosted by @lifesciences_GE tomorrow! More here: bit.ly/3wA6Aqt
00:00 - We’re proud to unveil positive topline results from our Ph2b IMPACT trial in #MASH, which position pemvidutide as the first product candidate to demonstrate significant MASH effects + #weightloss at just 24 weeks. Learn more here ir.altimmune.com/news-releases/…
00:00 - We’re proud to share that the @US_FDA has granted Fast Track designation to our novel, investigational GLP-1/glucagon dual receptor agonist, pemvidutide for the treatment of Alcohol Use Disorder (AUD). Learn more: ir.altimmune.com/news-releases/…
00:00 - We made public data from our 48-week Ph2 MOMENTUM trial of #pemvidutide, our investigational GLP-1/glucagon dual receptor agonist for the treatment of #obesity. Highlights include reductions in body weight & serum lipids, w/o cardiovascular complications. bit.ly/3GmG6tB
00:00
